{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:25:05Z","timestamp":1786987505967,"version":"build-2736575974"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cpcardiol.2026.103263","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:37:08Z","timestamp":1768840628000},"page":"103263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ocular manifestations of transthyretin amyloidosis and their diagnostic value in cardiology: A comprehensive review"],"prefix":"10.1016","volume":"51","author":[{"given":"Yongda","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingquan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103263_bib0001","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"38","key":"10.1016\/j.cpcardiol.2026.103263_bib0002","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.cpcardiol.2026.103263_bib0003","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103263_bib0004","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103263_bib0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103263_bib0006","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/IAE.0000000000003641","article-title":"Ophthalmologic involvement in patients with hereditary transthyretin amyloidosis","volume":"43","author":"Ruiz-Medrano","year":"2023","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0007","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/IAE.0000000000003296","article-title":"Ocular manifestations of Asp38Ala and Thr59Lys familial transthyretin amyloidosis","volume":"42","author":"Choi","year":"2022","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103263_bib0008","doi-asserted-by":"crossref","first-page":"128","DOI":"10.18240\/ijo.2023.01.19","article-title":"Clinical features of retinal amyloid angiopathy with transthyretin Gly83Arg variant","volume":"16","author":"Su","year":"2023","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.cpcardiol.2026.103263_bib0009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0002-9394(02)01838-X","article-title":"Vitreous opacities and outcome of vitreous surgery in patients with familial amyloidotic polyneuropathy","volume":"135","author":"Koga","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103263_bib0011","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Transthyretin","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"15","key":"10.1016\/j.cpcardiol.2026.103263_bib0012","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.2174\/092986712800269335","article-title":"Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?","volume":"19","author":"Palaninathan","year":"2012","journal-title":"Curr Med Chem"},{"issue":"23","key":"10.1016\/j.cpcardiol.2026.103263_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313158","article-title":"A brief journey through protein misfolding in transthyretin amyloidosis (ATTR amyloidosis)","volume":"22","author":"Gonzalez-Duarte","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"36","key":"10.1016\/j.cpcardiol.2026.103263_bib0014","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1021\/bi00151a036","article-title":"Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro","volume":"31","author":"Colon","year":"1992","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103263_bib0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103263_bib0016","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","article-title":"Fibril in senile systemic amyloidosis is derived from normal transthyretin","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 4","key":"10.1016\/j.cpcardiol.2026.103263_bib0017","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1073\/pnas.202495199","article-title":"Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity","volume":"99","author":"Hammarstr\u00f6m","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103263_bib0018","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1021\/bi101822y","article-title":"Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion","volume":"50","author":"Bourgault","year":"2011","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0019","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/path.1759","article-title":"Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology","volume":"206","author":"Bergstr\u00f6m","year":"2005","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/path.2411","article-title":"Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis","volume":"216","author":"Ihse","year":"2008","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103263_bib0021","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson","year":"2020","journal-title":"Amyloid"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103263_bib0022","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","article-title":"Familial amyloid polyneuropathy","volume":"10","author":"Plante-Bordeneuve","year":"2011","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103263_bib0023","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103263_bib0024","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10741-021-10098-6","article-title":"Clinical comparison of V122I genotypic variant of transthyretin amyloid cardiomyopathy with wild-type and other hereditary variants: a systematic review","volume":"27","author":"Goyal","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cpcardiol.2026.103263_bib0025","first-page":"103","article-title":"Genetic analysis of 11 families with hereditary transthyretin amyloidosis in China","volume":"368","author":"Liu","year":"2016","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0026","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41433-024-03445-y","article-title":"Hereditary vitreoretinal amyloidosis with transthyretin Gly83Arg variant, a long-term study","volume":"39","author":"Chen","year":"2025","journal-title":"Eye (Lond)"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103263_bib0027","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352","article-title":"Afro-Caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis","volume":"9","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0028","first-page":"235","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"5","author":"Ruberg","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103263_bib0029","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103263_bib0030","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103263_bib0031","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103263_bib0032","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1046\/j.1460-9592.2001.01228.x","article-title":"Holter monitoring in AL amyloidosis: prognostic implications","volume":"24","author":"Palladini","year":"2001","journal-title":"Pacing Clin Electrophysiol"},{"issue":"13","key":"10.1016\/j.cpcardiol.2026.103263_bib0033","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.cpcardiol.2026.103263_bib0034","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0035","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maceira","year":"2005","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103263_bib0036","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0037","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103263_bib0038","first-page":"143","article-title":"Systemic and ocular amyloidosis caused by Val30Met transthyretin","volume":"109","author":"Koga","year":"2002","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0039","first-page":"206","article-title":"Long-term course of vitreous opacities in patients with familial amyloid polyneuropathy after liver transplantation","volume":"128","author":"Kawaji","year":"2010","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41433-024-03445-y","article-title":"Hereditary vitreoretinal amyloidosis with transthyretin Gly83Arg variant, a long-term study","volume":"39","author":"Chen","year":"2025","journal-title":"Eye (Lond)"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103263_bib0041","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1001\/archopht.1990.01070130086036","article-title":"Vitreous amyloidosis associated with homozygosity for the transthyretin methionine-30 gene","volume":"108","author":"Sandgren","year":"1990","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103263_bib0042","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2005.05.028","article-title":"Ocular amyloid angiopathy associated with familial amyloidotic polyneuropathy caused by amyloidogenic transthyretin Y114C","volume":"112","author":"Kawaji","year":"2005","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103263_bib0043","first-page":"947","article-title":"The pathophysiology of ocular manifestations in familial amyloidotic polyneuropathy","volume":"66","author":"Oshitari","year":"2021","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103263_bib0044","doi-asserted-by":"crossref","first-page":"128","DOI":"10.18240\/ijo.2023.01.19","article-title":"Clinical features of retinal amyloid angiopathy with transthyretin Gly83Arg variant","volume":"16","author":"Su","year":"2023","journal-title":"Int J Ophthalmol"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103263_bib0045","first-page":"1106","article-title":"Lattice corneal dystrophy type II associated with familial amyloid polyneuropathy type IV","volume":"102","author":"Akiya","year":"1995","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0046","first-page":"73","article-title":"Usefulness of aqueous humor analysis in the diagnosis of vitreous amyloidosis in hereditary transthyretin amyloidosis","volume":"21","author":"Beir\u00e3o","year":"2014","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103263_bib0047","first-page":"793","article-title":"Prognosis of patients with familial amyloid polyneuropathy who underwent therapeutic vitrectomy for vitreous opacity","volume":"127","author":"Kawaji","year":"2009","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103263_bib0048","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0039-6257(95)80025-5","article-title":"Ocular amyloidosis, with special reference to the hereditary forms with vitreous involvement","volume":"40","author":"Sandgren","year":"1995","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0049","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41433-024-03445-y","article-title":"Hereditary vitreoretinal amyloidosis with transthyretin Gly83Arg variant, a long-term study","volume":"39","author":"Chen","year":"2025","journal-title":"Eye (Lond)"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103263_bib0050","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archneur.62.7.1057","article-title":"Transthyretin-related familial amyloidotic polyneuropathy","volume":"62","author":"Ando","year":"2005","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103263_bib0051","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/01.wco.0000245371.89941.eb","article-title":"Alcoholic neuropathy","volume":"19","author":"Koike","year":"2006","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103263_bib0052","doi-asserted-by":"crossref","first-page":"128","DOI":"10.18240\/ijo.2023.01.19","article-title":"Clinical features of retinal amyloid angiopathy with transthyretin Gly83Arg variant","volume":"16","author":"Su","year":"2023","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103263_bib0053","first-page":"1","article-title":"Ocular complications in familial amyloidotic polyneuropathy patients after domino liver transplantation","volume":"80","author":"Kawaji","year":"2005","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103263_bib0054","first-page":"522","article-title":"\"Floaters\"","volume":"21","author":"Schwartz","year":"2007","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.cpcardiol.2026.103263_bib0055","series-title":"Glaucoma","first-page":"156","author":"Salmon","year":"2020"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103263_bib0056","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103263_bib0057","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","article-title":"Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis","volume":"19","author":"Cavalcante","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0058","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ejhf.1974","article-title":"Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis","volume":"23","author":"Rosenblum","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0059","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103263_bib0060","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","article-title":"Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement","volume":"71","author":"Scully","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.cpcardiol.2026.103263_bib0061","first-page":"2495","article-title":"Transcatheter aortic valve replacement in patients with transthyretin cardiac amyloidosis: clinical outcomes and considerations","volume":"12","author":"Sperry","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0062","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Castano","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"24","key":"10.1016\/j.cpcardiol.2026.103263_bib0063","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0064","first-page":"110","article-title":"Impact of transcatheter aortic valve replacement on survival in patients with cardiac amyloidosis","volume":"82","author":"Dagan","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103263_bib0066","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0067","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103263_bib0068","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103263_bib0069","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/CIRCIMAGING.113.000683","article-title":"Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy","volume":"6","author":"Liu","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103263_bib0070","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.echo.2019.03.005","article-title":"Role of right ventricular strain measured by two-dimensional echocardiography in the diagnosis of cardiac amyloidosis","volume":"32","author":"Mo\u00f1ivas Palomo","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103263_bib0071","first-page":"94","article-title":"Multimodality imaging for the diagnosis and management of cardiac amyloidosis","volume":"22","author":"Seetharam","year":"2020","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103263_bib0072","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/jcm11030651","article-title":"Magnetic resonance for differential diagnosis of left ventricular hypertrophy: diagnostic and prognostic implications","volume":"11","author":"Aquaro","year":"2022","journal-title":"J Clin Med"},{"issue":"16","key":"10.1016\/j.cpcardiol.2026.103263_bib0073","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103263_bib0074","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103263_bib0075","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","article-title":"Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis","volume":"4","author":"Rapezzi","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0076","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcmg.2013.08.015","article-title":"CMR-based differentiation of AL and ATTR cardiac amyloidosis","volume":"7","author":"Dungu","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"24","key":"10.1016\/j.cpcardiol.2026.103263_bib0077","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0078","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"24","key":"10.1016\/j.cpcardiol.2026.103263_bib0079","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.cpcardiol.2026.103263_bib0080","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103263_bib0081","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103263_bib0082","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103263_bib0083","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103263_bib0084","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103263_bib0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103263_bib0086","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103263_bib0087","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103263_bib0088","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103263_bib0089","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"30","key":"10.1016\/j.cpcardiol.2026.103263_bib0090","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103263_bib0091","first-page":"347","article-title":"Management of cardiac amyloidosis in Italy: a national survey of the Italian Cardiac Amyloidosis Network (RIAC)","volume":"26","author":"Chimenti","year":"2025","journal-title":"G Ital Cardiol (Rome)"},{"issue":"Suppl 1","key":"10.1016\/j.cpcardiol.2026.103263_bib0092","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/13506129.2016.1272453","article-title":"Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?","volume":"24","author":"Aus dem Siepen","year":"2017","journal-title":"Amyloid"},{"issue":"16","key":"10.1016\/j.cpcardiol.2026.103263_bib0093","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.118.034338","article-title":"Fully automated echocardiogram interpretation in clinical practice","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014628062600006X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014628062600006X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:25:18Z","timestamp":1771377918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014628062600006X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S014628062600006X"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103263","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular manifestations of transthyretin amyloidosis and their diagnostic value in cardiology: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103263"}}